FDA approves crofelemer

FDA approved Fulyzaq crofelemer from Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) to treat non-infectious diarrhea in HIV/AIDS patients on antiretroviral therapy. Salix said it is still determining the price of Fulyzaq, which it plans to launch in the U.S. in March. Fulyzaq acts as a partial antagonist of cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channel. The drug's active ingredient is a purified proanthocyanidin oligomer extracted from the bark latex of the Amazonian tree Croton lechleri. Salix was up $2.01 to $42.48 on Wednesday. ...